Pomalidomide Combinations Are a Safe and Effective Option After Daratumumab Failure

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2023 Feb 13

PMID 36781500

Authors

Annamaria Brioli

Laura Gengenbach

Katia Mancuso

Mascha Binder

Thomas Ernst

Florian H Heidel

Thomas Stauch

Elena Zamagni

Inken Hilgendorf

Andreas Hochhaus

Monika Engelhardt

Marie von Lilienfeld-Toal

Affiliations

Soon will be listed here.

Abstract

Purpose: Outcomes of multiple myeloma (MM) patients who are refractory to daratumumab are dismal and no standard of treatment exists for this patients' population. Here, we investigate the role of pomalidomide combinations in daratumumab-refractory MM patients.

Methods: We performed a retrospective analysis of myeloma patients treated at four referral centers (three in Germany and one in Italy). Review chart identified 30 patients with relapsed and refractory myeloma, who progressed during treatment with daratumumab and were treated with pomalidomide-based combinations in the subsequent lines of therapy.

Results: Responses improved from 37% with daratumumab to 53% with pomalidomide. Of seven patients with extramedullary MM (EMM), four achieved a clinical stabilization with pomalidomide, including one patient with a long-lasting complete response. Median progression-free survival and overall survival were 6 and 12 months, respectively. Pomalidomide combinations were well tolerated, no patient discontinued treatment due to adverse events.

Conclusion: These data show that pomalidomide-based combinations can be an effective and safe salvage regimen for daratumumab-refractory patients, including those with EMM.

Citing Articles

Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options.

Mettias S, ElSayed A, Moore J, Berenson J Target Oncol. 2025; .

PMID: 39878864 DOI: 10.1007/s11523-024-01122-4.

Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma.

Parekh D, Tiger Y, Jamouss K, Hassani J, Zerdan M, Raza S Cancers (Basel). 2024; 16(17).

PMID: 39272790 PMC: 11394453. DOI: 10.3390/cancers16172931.

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

White D, Schiller G, Madan S, Lentzsch S, Chubar E, Lavi N Front Oncol. 2024; 14:1352281.

PMID: 38826786 PMC: 11140414. DOI: 10.3389/fonc.2024.1352281.

References

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R . Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013; 122(16):2799-806. DOI: 10.1182/blood-2013-03-488676. View

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

Palumbo A, Chanan-Khan A, Weisel K, Nooka A, Masszi T, Beksac M . Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 375(8):754-66. DOI: 10.1056/NEJMoa1606038. View

Lonial S, Weiss B, Usmani S, Singhal S, Chari A, Bahlis N . Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016; 387(10027):1551-1560. DOI: 10.1016/S0140-6736(15)01120-4. View

Van Oekelen O, Parekh S, Cho H, Vishnuvardhan N, Madduri D, Richter J . A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2020; 61(9):2208-2215. DOI: 10.1080/10428194.2020.1805111. View

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L . Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10192):29-38. DOI: 10.1016/S0140-6736(19)31240-1. View

Gandhi U, Cornell R, Lakshman A, Gahvari Z, McGehee E, Jagosky M . Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33(9):2266-2275. PMC: 6820050. DOI: 10.1038/s41375-019-0435-7. View

Lonial S, Lee H, Badros A, Trudel S, Nooka A, Chari A . Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2019; 21(2):207-221. DOI: 10.1016/S1470-2045(19)30788-0. View

10.

Dimopoulos M, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M . Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018; 379(19):1811-1822. DOI: 10.1056/NEJMoa1805762. View

11.

Dimopoulos M, Quach H, Mateos M, Landgren O, Leleu X, Siegel D . Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020; 396(10245):186-197. DOI: 10.1016/S0140-6736(20)30734-0. View

12.

Richardson P, Oriol A, Beksac M, Liberati A, Galli M, Schjesvold F . Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(6):781-794. DOI: 10.1016/S1470-2045(19)30152-4. View

13.

Moreau P, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6):495-505. PMC: 10587778. DOI: 10.1056/NEJMoa2203478. View

14.

Nooka A, Joseph N, Kaufman J, Heffner L, Gupta V, Gleason C . Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Cancer. 2019; 125(17):2991-3000. DOI: 10.1002/cncr.32178. View

15.

Facon T, Kumar S, Plesner T, Orlowski R, Moreau P, Bahlis N . Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019; 380(22):2104-2115. PMC: 10045721. DOI: 10.1056/NEJMoa1817249. View

16.

Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M . LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022; 36(5):1371-1376. PMC: 9061296. DOI: 10.1038/s41375-022-01531-2. View

17.

Chari A, Minnema M, Berdeja J, Oriol A, van de Donk N, Rodriguez-Otero P . Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022; 387(24):2232-2244. DOI: 10.1056/NEJMoa2204591. View

18.

Chari A, Vogl D, Gavriatopoulou M, Nooka A, Yee A, Huff C . Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019; 381(8):727-738. DOI: 10.1056/NEJMoa1903455. View

19.

San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M . Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14(11):1055-1066. DOI: 10.1016/S1470-2045(13)70380-2. View

20.

Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I . Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018; 132(24):2555-2563. DOI: 10.1182/blood-2018-07-863829. View